[go: up one dir, main page]

MA43445B1 - Modified antibodies binding to human fcrn and methods of use - Google Patents

Modified antibodies binding to human fcrn and methods of use

Info

Publication number
MA43445B1
MA43445B1 MA43445A MA43445A MA43445B1 MA 43445 B1 MA43445 B1 MA 43445B1 MA 43445 A MA43445 A MA 43445A MA 43445 A MA43445 A MA 43445A MA 43445 B1 MA43445 B1 MA 43445B1
Authority
MA
Morocco
Prior art keywords
methods
human fcrn
modified antibodies
antibodies binding
fcrn
Prior art date
Application number
MA43445A
Other languages
French (fr)
Other versions
MA43445A1 (en
Inventor
Guido Hartmann
Joerg Thomas Regula
Matthias Rueth
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2014/058417 external-priority patent/WO2014177460A1/en
Publication of MA43445A1 publication Critical patent/MA43445A1/en
Publication of MA43445B1 publication Critical patent/MA43445B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'un anticorps comportant une région fc présentant une liaison nulle à fcrn pour le transport d'un ligand soluble du récepteur, à partir de l'œil à travers la barrière hémato-oculaire dans la circulation sanguine.The present invention relates to the use of an antibody comprising an fc region exhibiting zero binding to fcrn for the transport of a soluble ligand of the receptor from the eye through the blood-ocular barrier into the bloodstream.

MA43445A 2014-04-25 2014-04-25 Modified antibodies binding to human fcrn and methods of use MA43445B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/058417 WO2014177460A1 (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use

Publications (2)

Publication Number Publication Date
MA43445A1 MA43445A1 (en) 2019-07-31
MA43445B1 true MA43445B1 (en) 2021-03-31

Family

ID=67439949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43445A MA43445B1 (en) 2014-04-25 2014-04-25 Modified antibodies binding to human fcrn and methods of use

Country Status (1)

Country Link
MA (1) MA43445B1 (en)

Also Published As

Publication number Publication date
MA43445A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201501063A1 (en) CONNECTING HUMAN FcRn MODIFIED ANTIBODIES AND METHODS OF THEIR APPLICATION
EP3808760A4 (en) COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP, OR CORRESPONDING SALT
MA44594B1 (en) Anti-ctla-4 Antibodies and Methods of Use thereof
MA43028B1 (en) Bispecific antibodies for pd1 and tim3
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
CY1122188T1 (en) THERAPEUTIC TREATMENT OF FIBRODYSPLASIA OSTEOPIUS PROGRESSIVE
JOP20190248A1 (en) Trem2 antigen binding proteins and uses thereof
HK1249854A1 (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
MX376663B (en) Antibodies against FC receptor-like 5 (FCRH5).
EP3665195A4 (en) MODIFIED FC ANTIBODY VARIANTS FOR IMPROVED SERIC HALF-LIFE
JOP20190236A1 (en) Anti-ILT4 Antibodies and Antigen-Binding Fragments
CR20170383A (en) ANTI-CD3 ANTIBODIES, ANTI-CD-123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
GEAP202014437A (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
EA201691438A1 (en) ANTIBODY WHICH IS CONNECTED WITH ERBB-2 AND ERBB-3
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
MA40913A (en) ANTIBODY-DRUG CONJUGATES
EA201890064A1 (en) SYSTEM OF CAPACITIES AND THEIR CONNECTIONS
EA201890078A1 (en) ANTIBODY
MX2019012419A (en) Use of klk5 antagonists for treatment of a disease.
EA201691212A1 (en) NEW ANTIBODY AGAINST NETRINE-1
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies
MA38816B1 (en) Sulfamidase modified and its production
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
MA43445B1 (en) Modified antibodies binding to human fcrn and methods of use